期刊文献+

血清人附睾分泌蛋白4联合糖类抗原125诊断卵巢癌的价值分析 被引量:2

Value analysis of serum human epididymis secretory protein 4 combined with carbohydrate antigen 125 in the diagnosis of ovarian cancer
下载PDF
导出
摘要 目的:探讨血清人附睾分泌蛋白4(HE4)联合糖类抗原125(CA125)诊断卵巢癌的临床价值。方法:选择32例卵巢癌患者、35例卵巢良性肿瘤患者以及30例健康女性为研究对象,比较3组间血清HE4和CA125水平差异,计算血清HE4、CA125和HE4+CA125诊断卵巢癌患者的灵敏度、特异度和准确度。结果:卵巢良性肿瘤组和卵巢癌组患者血清HE4和CA125水平均明显高于对照组(P<0.05),且卵巢癌组患者血清HE4和CA125水平均明显高于卵巢良性肿瘤组(P<0.05)。血清HE4诊断卵巢癌的灵敏度、特异度、阳性预测值、阴性预测值和准确度均明显高于CA125,而联合检测HE4和CA125的灵敏度、特异度、阳性预测值、阴性预测值和准确度均明显高于任何一个单项检测(P<0.05)。结论:卵巢癌患者血清HE4和CA125水平明显升高,联合检测血清HE4和CA125可以提高诊断卵巢癌的准确性。 Objective:To explore the clinical value of serum human epididymis secretory protein 4(HE4) combined with carbohydrate antigen 125(CA125) in the diagnosis of ovarian cancer.Methods:32 patients with ovarian cancer,35 patients with benign ovarian tumor and 30 cases of healthy women were selected as the study objects.The differences of serum HE4 and CA125 level in 3 groups were compared.The sensitivity,specificity and accuracy of serum HE4、CA125 and HE4+CA125 in the diagnosis of ovarian cancer were calculated.Results:The serum HE4 and CA125 level of the benign ovarian tumor group and the ovarian cancer group were all significantly higher than those of the control group(P < 0.05),and serum HE4 and CA125 level of the ovarian cancer group were significantly higher than those of the benign ovarian tumor group(P < 0.05).The sensitivity,specificity,positive predictive value,negative predictive value and accuracy of serum HE4 were significantly higher than those of CA125,and the sensitivity,specificity,positive predictive value,negative predictive value and accuracy of combined detection of HE4 and CA125 were significantly higher than those of any single detection(P < 0.05).Conclusion:The serum HE4 and CA125 level of ovarian cancer are elevated significantly,combined detection of serum HE4 and CA125 can improve the accuracy of the diagnosis of ovarian cancer.
作者 杨冬梅 Yang Dongmei(Maternal and Child Health Hospital of Anyang City,Henan Province 455000)
出处 《中国社区医师》 2016年第11期140-141,共2页 Chinese Community Doctors
关键词 卵巢癌 血清人附睾分泌蛋白4 糖类抗原125 Ovarian cancer Serum human epididymis secretory protein 4 Carbohydrate antigen 125
  • 相关文献

参考文献9

二级参考文献92

  • 1杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量:17
  • 2丰有吉.妇产科学[M].第2版.北京:人民卫生出版社,2010:68-69. 被引量:205
  • 3Moore RG,Mcmeekin DS,Brown AK,et al.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.Gynecol Oncol,2009,112:40-46. 被引量:1
  • 4Hellstrom(o) I,Hellstrom KE SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.Adv Exp Med Biol,2008,622:15-21. 被引量:1
  • 5Bast Jr RC,Feeney M,Lazarus H,et al.Reactivity of amonoclonal antibody with human ovarian carcinoma.J Clin Invest,1981,68:1331-1337. 被引量:1
  • 6Kabawat SE,Bast RC Jr,Bhan AK,et al.Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC 125.Int J Gynecol Pathol,1983,2:275-285. 被引量:1
  • 7Riedinger JM,wafnart J,Rieolleau G,et al.CA125 halflife and CA125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome:results of a French muhicemrie study.Annas of Oncology,2006,17:1234-1238. 被引量:1
  • 8Riedinger JM,Bonnetain F,Eche N,et al.Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors:results of a muhicentric.French study Bull Cancer,2007,94:287-295. 被引量:1
  • 9Kim HS,Park NH,Chung HH,et al.Serum CA125 levelafter 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responderK survival in patients with advanced epithelial ovarian cancer.Onkologie,2008,31:315-320. 被引量:1
  • 10Rustin GJ,Marples M,Nelstmp AE,et al.Use of CA125to define progression of ovarian cancer in patients with persistently elevated levels.J Clin Oncol,2001,19:4054-4057. 被引量:1

共引文献180

同被引文献21

  • 1Ferlay J, Soerjomataram I, Ervik M, et al. Globocan2012 vl. 0, cancer incidence and mortality worldwide: IARC cancer base No. 11[Internet] ,international agency for re- search on cancer, Lyon, France[EB/OL]. [2015-08-12]. http ..//globocan. iarc. fr. 被引量:1
  • 2Foster T. A review of the current evidence for mainte- nance therapy in ovarian cancer[J]. Gynecol OncoI, 2009, 115 (2) : 290-301. 被引量:1
  • 3Markmann S, Gerber B, Briese V. Prognostic value of Ca 125 levels during primary therapy [J]. Anticancer Res, 2007,27(4A):1837-1839. 被引量:1
  • 4Kirchhoff C. Molecular characterization of epididymal proteins[J]. Rev Reprod, 1998,3 (1) :86-95. 被引量:1
  • 5Drapkin R, von Horsten HH, Lin Y, et al. Human epidid- ymis protein4(HE4) is a secreted glycoprotein that is o- ver expressed by serous andendometrioid ovarian carcino- mas[J]. Cancer Res,2005,65(6):2162-2169. 被引量:1
  • 6Medeiros LR, Rosa DD, da Rosa MI, et al. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review[J]. Eur J Obstet Gynecol Reprod Biol, 2009,142(2) : 99-105. 被引量:1
  • 7Steffensen KD, Waldstrm M, Brandslund I, et al. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients[J].Int J Gynecol Cancer, 2012,22 (9): 1474-1482. 被引量:1
  • 8Stiekema A, Lok CA, Kenter GG, et al. A predictive model combining human epididymal protein 4 and radiologic fea- tures for the diagnosis of ovarian cancer[J]. Gynecol On- :ol, 2014,132(3) : 573-537. 被引量:1
  • 9刘亚南,叶雪,程洪艳,成夜霞,付天云,陈军,昌晓红,崔恒.人附睾分泌蛋白4联合CA125在卵巢恶性肿瘤与子宫内膜异位症鉴别诊断中的价值[J].中华妇产科杂志,2010,45(5):363-366. 被引量:55
  • 10杨辰,宋妙丽,仲汉彬,于静萍,刘芬菊.血清人附睾分泌蛋白4、CA125及卵巢癌风险模型在卵巢肿瘤鉴别诊断中的价值[J].苏州大学学报(医学版),2010,30(4):795-798. 被引量:15

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部